Nuclera (NUCLERA NUCLEICS LTD.)
Company Snapshot
Founded: 2013
Entity Type: Private
Region: U.K.
Headquarter: Cambridge, U.K.
Key Geographics: U.K., U.S.
Corporate Address: One Vision Park, Station Road, Impington, Cambridge, CB24 9NP U.K. Tel: +44-1223-625095 www.nuclera.com
Company Overview
Nuclera Nucleics is developing next-generation DNA synthesis technology based on proprietary engineered enzymes. The enzymes, terminal deoxynucleotidyl transferases (TdT) allow production of genes and genome libraries. Nuclera’s goal is to make synthetic DNA accessible to small- and mid-sized laboratories.
Recently Nuclera raised $15.5 million in additional funding in a Series B financing round totaling up to $58 million. The company has raised a total of $83.3 million to develop its proprietary DNA synthesis technology. The additional investments will be used to accelerate the commercial launch of the eProtein desktop bioprinter.
Nuclera (NUCLERA NUCLEICS LTD.) In Reports
Nuclera (NUCLERA NUCLEICS LTD.) In News
Company's Business Segments
- Products : Instrument, Cartridge, Reagents, Software, Others
- Services : eProtein Discovery System, Others
Applications/End User Industries
- Biotechnology
- Healthcare
- Pharmaceuticals
- Research and Academics
- Life Sciences